Navigation Links
Researchers find alternative cholesterol-lowering drug for patients who can't tolerate statins
Date:3/11/2013

SAN FRANCISCO Heart patients who can't tolerate the side effects of cholesterol-lowering drugs may have a new option, according to a new study by researchers from the Intermountain Heart Institute at Intermountain Medical Center in Salt Lake City.

Researchers found that pitavastatin, a newer cholesterol-lowering drug, may reduce the risk of heart attack, stroke and even death in up to 68 percent of patients with high cholesterol who can't tolerate other cholesterol-lowering medications due to side effects.

Researchers are presenting the results of this study today (Monday, March 10) at the American College of Cardiology's Annual Scientific Session in San Francisco.

The findings are important because up to 15 percent of the nation's heart patients can't tolerate other statin medications, currently the most effective cholesterol-lowering agents available.

"Many of the patients who were not able to tolerate other statins developed side effects, such as myalgia or severe muscle aches. However, our study shows that pitavastatin may be a more tolerable statin that patients can take that will be effective in lowering their cholesterol, and may even save their lives," said Brent Muhlestein, MD, cardiologist at the Intermountain Heart Institute at Intermountain Medical Center, and lead researcher for the study.

The Research

The research team identified 40 patients who had tried at least two other statins and tested them to see if they could tolerate pitavastatin, and if it was effective in lowering their LDL or "bad" cholesterol.

All patients received initial baseline testing, including fasting LDL cholesterol levels. They were then given 2 mg of pitavastatin (also known as Livalo), per day. Those who could tolerate it were then tested again to see if their LDL cholesterol had been reduced.

Findings

  • 68 percent of the study participants were able to tolerate the side-effects of pitavastatin.

  • Pitavastatin lowered cholesterol by an average of 34 percent.

  • Patients who could best tolerate the drug were males with no history of heart disease or diabetes.

"We're excited about these findings," said Dr. Muhlestein. "If patients are having a hard time taking older statins, they should try this newer option. We believe the side effects of this drug differ from other statins because pitavastatin is water-soluble and metabolizes differently."

The Intermountain study also confirmed that pitavastatin is far more effective than any other non-statin option.

Ezetimibe (Zetia), for example, is a drug that blocks the absorption of cholesterol and is a non-statin treatment option, but it only lowers bad cholesterol by 18 to 20 percent. Another option is healthy margarine, but that only lowers it by 5 to 10 percent. Pitavastatin, by contrast, lowered cholesterol by an average of 34 percent, according to the study.


'/>"/>

Contact: Jess C. Gomez
jess.gomez@imail.org
801-718-8495
Intermountain Medical Center
Source:Eurekalert

Related biology news :

1. Researchers develop tools for discovering new species
2. University of Illinois researchers develop AFM-IR for nanometer scale chemical identification
3. IRB Barcelona researchers discover mechanism that regulates steroid hormone production in Drosophila
4. Researchers discover gateway in nucleus has a second important job no one noticed before
5. Researchers explain a key developmental mechanism for the first time in plants
6. Researchers find molecular switch turning on self-renewal of liver damage
7. UGA researchers shed light on ancient origin of life
8. Researchers discover workings of brains GPS system
9. Researchers propose new solution to ensure biofuel plants dont become noxious weeds
10. Temple researchers discover key to heart failure, new therapies on horizon
11. Researchers discover gene that causes obesity in mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
(Date:4/13/2016)... -- IMPOWER physicians supporting Medicaid patients in Central ... in telehealth thanks to a new partnership with higi. ... patients can routinely track key health measurements, such as ... when they opt in, share them with IMPOWER clinicians ... retail location at no cost. By leveraging this data, ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network for ... Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is to ... are designed, built and brought to market. , The Design Lab is Supplyframe’s ...
(Date:6/23/2016)... NC (PRWEB) , ... June 23, 2016 , ... In ... University Hospital in Denmark detail how a patient who developed lymphedema after being treated ... tissue. The results could change the paradigm for dealing with this debilitating, frequent side ...
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... -- On Wednesday, June 22, 2016, the NASDAQ ... Dow Jones Industrial Average edged 0.27% lower to finish at ... Stock-Callers.com has initiated coverage on the following equities: Infinity Pharmaceuticals ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... Learn more about these stocks by accessing their free trade ...
Breaking Biology Technology: